NEW YORK (GenomeWeb) – Gastric cancer patients with MUC16 gene mutations have higher tumor mutational loads than those who do not, according to a new study. These gene mutations could also identify patients who might benefit from immunotherapy.

More than 26,000 people are diagnosed with gastric cancer each year in the US, according to the National Cancer Institute, and slightly less than a third of patients survive five years.